Top Banner
120

Case Presentations 2

May 07, 2015

Download

Health & Medicine

Gamal Agmy
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Case Presentations 2
Page 2: Case Presentations 2

Case Presentations

Gamal Rabie Agmy ,MD ,FCCP

Professor of Chest Diseases, Assiut University

Page 3: Case Presentations 2

Case No. 4

Page 4: Case Presentations 2

• A 48-year-old woman is referred to you with chest heaviness and shortness of breath on exertion.

• She was recently investigated by a cardiologist who concluded her symptoms were noncardiac in origin after a normal angiogram.

Page 5: Case Presentations 2

• She has also noticed increasing fatigue for the past 6 months. She mentions she works in a stressful environment as a critical care nurse. She denies any associated wheezing, cough, nocturnal symptoms, radiation of chest discomfort, palpitations, or syncope.

• Her symptoms were not relieved with nitroglycerin spray. Her history is otherwise negative, she is a lifelong nonsmoker, and she is on no medications.

• Physical examination results are normal.

Page 6: Case Presentations 2

Pulmonary Function Test Results

Page 7: Case Presentations 2

• A methacholine challenge test:

Demonstrates a PC20 (percent concentration associated with a 20% fall in the FEV1) of 6.00 mg/mL.

Her symptoms were not reproduced during the methacholine challenge test.

• The patient underwent cardiopulmonary exercise testing, revealing the following data:

Page 8: Case Presentations 2

Cardiopulmonary Exercise Test Results

Page 9: Case Presentations 2

• There were no arrhythmias, significant ST segment, or T-wave changes.

• The patient reported discontinuing exercise because of shortness of breath.

• Spirometry performed immediately following exercise was done.

Page 10: Case Presentations 2

Results of Spirometry After Exercise

Page 11: Case Presentations 2
Page 12: Case Presentations 2

The results from these investigations are most consistent with which of the following?

• A. Exercise-induced bronchoconstriction (EIB).

• B. Deconditioning.

• C. Vocal cord dysfunction.

• D. Primary hyperventilation syndrome

Page 13: Case Presentations 2

• This patient has shortness of breath and chest discomfort with exertion in the setting of normal pulmonary function and a negative result of a methacholine challenge test.

• Cardiopulmonary exercise testing reveals normal performance and values, except for a 15% decrease in the FEV1 immediately following exercise, consistent with a diagnosis of EIB (choice A is correct).

Page 14: Case Presentations 2

• Exercise testing shows normal aerobic and work capacity with no significantly abnormal cardiac or respiratory responses (choice B is incorrect).

• While the patient works in a stressful occupation, there are no findings consistent with primary hyperventilation syndrome such as an erratic breathing pattern and hyperventilation, which is excessive for the simultaneous metabolic load (choice D is incorrect).

• Examination of the exercise tidal flow-volume curves, both at rest and with exercise, does not reveal any changes consistent with central airway obstruction (choice C is incorrect).

Page 15: Case Presentations 2

• Exercise associated airway narrowing occurs in the majority of patients with asthma. Although patients often deny or do not recognize other symptoms of asthma, these symptoms can often be detected with a careful clinical history.

• It is important to understand the diagnosis of EIB is not excluded by a negative result of a methacholine challenge test, although it is most commonly positive in this clinical setting. In this instance, the patient underwent cardiopulmonary exercise testing to objectively understand the patient’s symptoms of activity limitation, which was normal, as the patient demonstrated normal work and aerobic capacity.

Page 16: Case Presentations 2

• However, spirometry following exercise did reveal a significant decrement in the FEV1, which responded to the administration of a bronchodilator. Not mentioned is that the patient’s symptoms were also reproduced immediately following exercise. These findings confirm the diagnosis of EIB, although if these results were not demonstrated and clinical suspicion for EIB remained, a more specific EIB exercise protocol would have been indicated

Page 17: Case Presentations 2

• This typically consists of high intensity exercise on a treadmill or bicycle ergometer of 6 to 8 min duration intended to rapidly achieve the highest possible level of ventilation for 4 to 6 min. There should not be a significant warm-up period, which may lead to tolerance or refractoriness to EIB. This can also occur if exercise duration exceeds 12 min.

• A fall in the FEV1 of 10% or more is interpreted as abnormal, while a 15% or more fall is considered to be diagnostic. An appropriate post exercise testing schedule is 1, 3, 5, 10, 15, 20, and 30 min after cessation of exercise, although if the FEV1 has returned from its nadir to the baseline level or greater, spirometry testing may be terminated at 20 min post exercise.

Page 18: Case Presentations 2

• These bronchoconstriction responses may also occasionally be demonstrated with eucapnic voluntary hyperventilation or cold air challenge. While a positive response (ie, a fall in the FEV1) may also be seen in patients with upper airway obstruction or vocal cord dysfunction, the cases can be readily distinguished from EIB by examination of the exercise tidal flow-volume curves

Page 19: Case Presentations 2

So the finial diagnosis is

• A. Exercise-induced bronchoconstriction (EIB).

• B. Deconditioning.

• C. Vocal cord dysfunction.

• D. Primary hyperventilation syndrome

Page 20: Case Presentations 2

• Exercise testing shows normal aerobic and work capacity with no significantly abnormal cardiac or respiratory responses (choice B is incorrect).

• While the patient works in a stressful occupation, there are no findings consistent with primary hyperventilation syndrome such as an erratic breathing pattern and hyperventilation, which is excessive for the simultaneous metabolic load (choice D is incorrect).

• Examination of the exercise tidal flow-volume curves, both at rest and with exercise, does not reveal any changes consistent with central airway obstruction (choice C is incorrect).

Page 21: Case Presentations 2

Case No. 5

Page 22: Case Presentations 2

• A 74-year-old man with a history of mild COPD has a 3-month history of worsening dyspnea on exertion.

• He was seen by his primary care provider 3 weeks ago, diagnosed with a COPD exacerbation, and received a 5-day course of azithromycin that did not provide much relief.

• He now notes a nonproductive cough and intermittent low-grade fevers.

Page 23: Case Presentations 2

• He has no other medical problems and takes no regular medications. He smoked 1 pack of cigarettes a day for 30 years but quit 25 years ago.

• He denies taking any over-the-counter medications or supplements.

• He has no pets or other unusual exposures, and he has not travelled out of the United States

Page 24: Case Presentations 2

• Vital signs on admission are only remarkable for a temperature of 37.9C and an oxygen saturation of 89% on 4 L/min nasal cannula.

• Physical examination is notable for diffuse inspiratory crackles.

• There is no clubbing, cyanosis, or edema.

Page 25: Case Presentations 2

His chest radiograph:

Page 26: Case Presentations 2

• A CBC reveals a WBC count of 12,300/L (12.3 × 109/L) with 55% neutrophils, 3% bands, 30% lymphocytes, 4% monos, and 8% eosinophils; hemoglobin level of 14.2 g/dL (142 g/L); and a platelet count of 223 × 103/L (223 × 109/L). His electrolyte levels are normal.

• His erythrocyte sedimentation rate (ESR) is 52 mm/h.

• C-reactive protein level is 8.2 mg/L (78.1 nmol/L)

Page 27: Case Presentations 2

• Serum IgE level is not markedly elevated.

• Total eosinophil count is 400/L (0.400 × 109/L).

• Cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA) findings are negative.

• Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) findings are positive at 1:80.

Page 28: Case Presentations 2

• He is admitted to the hospital and started on a regimen of broad-spectrum antibiotics.

• Over the next 3 days, his symptoms and radiograph worsen, and IV methylprednisolone, 60 mg tid is added.

Page 29: Case Presentations 2

A CT scan of the chest is obtained

Page 30: Case Presentations 2

• A bronchoscopy is performed and is nondiagnostic; no organisms are seen and there are no eosinophils on cell count.

• His oxygen requirement remains high and a thoracoscopic lung biopsy is performed

Page 31: Case Presentations 2

What is your diagnosis?

• A. Acute interstitial pneumonia (AIP).

• B. Cryptogenic organizing pneumonia (COP).

• C. Nonspecific interstitial pneumonia (NSIP).

• D. Chronic eosinophilic pneumonia (CEP).

Page 32: Case Presentations 2

• This patient’s clinical history and imaging could be consistent with any of the diagnoses listed above.

• The lung biopsy specimen, however, reveals a uniform temporal appearance with preservation of the lung architecture. • There is fibroblastic tissue within the alveolar airspace

and the lumina of the respiratory bronchioles without evidence of vasculitis or granuloma formation. These changes are classic for COP (choice B is correct).

Page 33: Case Presentations 2

• This organizing pneumonia pattern can be secondary to collagen vascular disease, infection, or drug reactions.

• When the cause is not known, the term cryptogenic organizing pneumonia is used. Although this patient may have had an infection early in his course, nothing could be identified after thorough evaluation in the hospital

Page 34: Case Presentations 2

• Patients with COP often present with a subacute illness, typically complaining of cough and dyspnea.

• Systemic symptoms such as fever, night sweats, and weight loss are common.

• Examination of the lungs will typically reveal crackles. Laboratory findings include an elevated ESR and C-reactive protein.

Page 35: Case Presentations 2

• Chest radiographs will reveal diffuse, patchy opacities, typically in the subpleural or lower lung fields.

• CT scan features include ground-glass attenuation and consolidation, which is either peribronchial or subpleural, as in this patient. Although relapses and chronic fibrosis can occur, most patients will recover after receiving a course of oral corticosteroids

Page 36: Case Presentations 2

• As mentioned above, the radiographic features of this case are not specific, and the pattern seen could also be consistent with AIP, NSIP, and given the subpleural predominance, CEP.

• The pathologic features, however, are distinctive. The hallmark pathologic finding in AIP is diffuse alveolar damage, with alveolar wall thickening, airspacem filling with proteinaceous exudates, and hyaline membranes along the airways. None of these features is present in this patient (choice A is incorrect).

• Classic features of CEP (interstitial and alveolar eosinophils, interstitial fibrosis, and eosinophilic microabscesses) are also absent (choice D is incorrect).

Page 37: Case Presentations 2

• NSIP is histologically characterized by interstitial inflammation and fibrosis that is temporally uniform without specific features that allow the identification of other idiopathic pneumonias, such as the temporal heterogeneity and prominent honeycombing of usual interstitial pneumonia or the numerous alveolar macrophages of desquamative interstitial pneumonitis and respiratory bronchiolitis-associated interstitial lung disease. Although small foci of organizing pneumonia can be seen, this is not the dominant feature (choice C is incorrect).

Page 38: Case Presentations 2

Idiopathic Interstitial Pneumonias

Gamal Rabie Agmy ,MD ,FCCP

Professor of Chest Diseases, Assiut University

Page 39: Case Presentations 2

Idiopathic Interstitial

Pneumonias

Page 40: Case Presentations 2

7 histological categories

• Usual interstitial pneumonia (UIP)

• Nonspecific interstitial pneumonia (NSIP)

• Organising pneumonia (OP)*

• Diffuse alveolar damage (DAD)

• Desquamative interstitial pneumonia (DIP)**

• Respiratory bronchiolitis (RB)

• Lymphocytic interstitial pneumonia (LIP)

* previously BOOP

** previously AMP

Page 41: Case Presentations 2

Correlation with HRCT patterns

7 clinical-radiological-pathological categories

ATS/ERS International Multidisciplinary Consensus Classification of the

Idiopathic Interstitial Pneumonias, AJRCCM Vol 165. pp 277-304, 2002

UIP

+ NSIP

+ OP

+ DAD

+

DIP

+ RB

+

LIP

+

=

IPF

=

NSIP =

COP

=

AIP =

DIP

=

RB-ILD =

LIP

Page 42: Case Presentations 2

Histology:

• Heterogeneous appearance

ü(hardly any inflammation)

• Temporal heterogeneity

Old + new fibrosis (fibroblastic foci)

IPF/UIP „disease status‟

Page 43: Case Presentations 2

Non-specific interstitial pneumonia ‟IIP-NSIP cellular / fibrotic variant‟

• temporal uniformity on biopsy

• no / few fibroblastic foci

• fine reticulation

• ground glass

Page 44: Case Presentations 2

Cryptogenic organising

pneumonia

(BOOP)

• patchy consolidations (95%)

• perilobular opacity (50%)

Ujita, Radiology 2004; 232: 757-61

Page 45: Case Presentations 2

Congestion & oedema

Exudative phase

Acute interstitial

pneumonia

acute onset, with systemic features: idiopathic ARDS

granulocytes + occasional lymphocytes; debris

survival from diagnosis often days despite mechanical support

Page 46: Case Presentations 2

Desquamative interstitial pneumonia (AMP)

smoker

BAL: AM+++N+E+L

Page 47: Case Presentations 2

Respiratory bronchiolitis

associated interstitial lung disease

cigarette smoker

obstructive or restrictive lung function

AM with smoker’s inclusions on BAL

Page 48: Case Presentations 2

LIP Lymphocytic interstitial

pneumonia

AIDS

lymphoproliferative

rheumatological

idiopathic (rare)

lymphocytes on BAL

Page 49: Case Presentations 2

Scenario 1: HRCT appearances are

pathognomonic

Page 50: Case Presentations 2

To be useful in the routine diagnosis of IIP, a test MUST be

good at diagnosing IPF

Page 51: Case Presentations 2

IPF/usual interstitial pneumonia

Page 52: Case Presentations 2
Page 53: Case Presentations 2
Page 54: Case Presentations 2

Key conclusion

• Typical HRCT features of IPF in association with a compatible clinical profile obviate surgical biopsy

BUT

• Atypical features on HRCT for IPF do NOT exclude the diagnosis

Page 55: Case Presentations 2

Scenario 2: HRCT and clinical features

are, together, diagnostic

Page 56: Case Presentations 2

RBILD

• Exaggerated form of smoking-related respiratory bronchiolitis

• Generally benign/self limited vs survival

• Significant symptoms/functional impairment

• Is a thoracoscopic biopsy necessary to make the diagnosis?

Page 57: Case Presentations 2
Page 58: Case Presentations 2

RBILD vs HP

Ask the patient!

BAL: lymphocytosis vs

pigmented macrophages

Page 59: Case Presentations 2

Key conclusion

The combination of HRCT, smoking and exposure history and BAL allows most RBILD patients to be diagnosed

non-invasively

Page 60: Case Presentations 2

Scenario 3: Diagnoses in which a

biopsy is required

Page 61: Case Presentations 2
Page 62: Case Presentations 2
Page 63: Case Presentations 2

Is an HRCT diagnosis of NSIP

inherently invalid?

The key concept of NSIP sub-groups

“If my pathologist tells me the biopsy shows NSIP, then my job has only just begun”

Page 64: Case Presentations 2

Scenario 4: Clinico-radiologic sub-groups

• Clinical features of IPF, HRCT overlap….

• Organizing pneumonia variant

• HP variant

• Connective tissue disease

• Post diffuse alveolar damage

• Smoking related?

Page 65: Case Presentations 2

The OP variant of NSIP

Nagai S. Eur Respir J 1998; 12:1010-1019

Kim TS. AJR 1998; 171:1645-1650.

Consolidation a prominent feature on CT (admixed with ground-glass/reticular elements)

A component of organizing pneumonia (<10%) often present at biopsy

Page 66: Case Presentations 2
Page 67: Case Presentations 2

The concept of “fibrosing organizing

pneumonia”

Does this equate with the “OP variant” of NSIP?

Page 68: Case Presentations 2

NSIP presenting with the clinical

features of IPF

• A rather different HRCT profile (compared to the organizing pneumonia variant)

• Organizing pneumonia, nodules not present on HRCT

• Predominant findings are ground-glass attenuation, fine reticulation, traction bronchiectasis

Page 69: Case Presentations 2

NSIP presenting with the clinical

features of IPF

• A rather different HRCT profile (compared to the organizing pneumonia variant)

• Organizing pneumonia, nodules not present on HRCT

• Predominant findings are ground-glass attenuation, fine reticulation, traction bronchiectasis

Page 70: Case Presentations 2
Page 71: Case Presentations 2
Page 72: Case Presentations 2

Key conclusion

NSIP should be separated into clinico-radiologic sub-groups.

Page 73: Case Presentations 2

Typical COP

• HRCT is often less discriminatory (vis a vis diagnosis) than serial chest radiography

• Evanescent (“immunological disorders”) versus fixed consolidation (alveolar cell cancer, non-bacterial infection)

• HRCT valuable in disclosing fibrosing variants

Page 74: Case Presentations 2

Lee JS. JCAT 2003; 27:260-265.

• 26 patients with histopathologic diagnosis of organizing pneumonia (“BOOP”)

• Persistent or progressive disease on HRCT despite treatment in 35%

• Predominant consolidation/nodules = good outcome

• Reticular abnormalities on HRCT = bad outcome

Page 75: Case Presentations 2

11-99

Page 76: Case Presentations 2

08-00

Page 77: Case Presentations 2

02-2001

Page 78: Case Presentations 2

Key conclusion

The greatest utility of HRCT in COP is to identify patients progressing or more

likely to progress to fibrosis

Page 79: Case Presentations 2

Scenario 5: Prognosis based on

reconciling HRCT and biopsy

Page 80: Case Presentations 2

Fibrotic NSIP

Page 81: Case Presentations 2

NSIP…. or is it really UIP?

UIP

Page 82: Case Presentations 2

Scenario 6: Prognosis based on

reconciling baseline data and disease

behaviour

Page 83: Case Presentations 2

Essentially, biopsy and HRCT are “silver standards” against the true clinical “gold standard” of disease

behaviour/ outcome

Page 84: Case Presentations 2

The real utility of the ATS/ERS

classification……….

Page 85: Case Presentations 2

What clinicians need from a

classification….

• Captures clusters of disease behaviour

• Articulates logical therapeutic goals

• Makes approach to monitoring obvious

Page 86: Case Presentations 2

This can be achieved

Page 87: Case Presentations 2

A classification based on pragmatic

management ...

• Cause

• Predominant morphologic abnormality

• Severity

• Longitudinal behaviour

Integrate these

Page 88: Case Presentations 2

Self-limited inflammation

• Examples: hypersensitivity pneumonitis, sarcoidosis, drug-induced lung disease

• Outcome good

• Avoidance of antigen, where applicable, crucial

• Repeated attempts to limit treatment justified

• Monitor to confirm disease regression

Page 89: Case Presentations 2

Stable/indolent fibrotic disease

• Diagnosis often incidental: CTD, hypersensitivity pneumonitis, sarcoidosis

• Key is not to over-react

• Management: MICO therapy…..

• Monitor to confirm disease stability

Page 90: Case Presentations 2

“Indolent disease”

MICO:

Masterful Inactivity

with Cat-like Observation

The role of the doctor is to amuse the patient while nature takes its course

(Voltaire)

Page 91: Case Presentations 2

Major inflammation with variable

fibrosis

• Severe sarcoidosis, hypersensitivity pneumonitis, drug-induced lung disease

• Key is distinguishing these cases from extensive irreversible fibrotic disease

• Essential to treat vigorously

• Monitor early to establish best treated PFT and later to exclude relapse

Page 92: Case Presentations 2

Inexorably progressive fibrosis

• Sarcoidosis, hypersensitivity pneumonitis

• Key to management is to find the right balance between slowing progression and poisoning the patient

• Monitor to evaluate rate of progression

Page 93: Case Presentations 2

Explosive ILD

• Sudden onset of disease. Idiopathic, “cryptogenic fibrosing alveolitis”

• Often life-threatening

• Exact diagnosis usually uncertain

• Key issue: biopsy on ventilator?

• Policy of “treat the treatable”

• Very stressful for doctors, patients and relatives

Page 94: Case Presentations 2

We investigate to distinguish between…….

• Self-limited inflammation

• Stable fibrotic disease

• Major inflammation with variable fibrosis

• Inexorably progressive fibrosis

• Explosive ILD

Page 95: Case Presentations 2

What clinicians need from a

classification….

• Captures clusters of disease behaviour

• Articulates logical therapeutic goals

• Makes approach to monitoring obvious

Page 96: Case Presentations 2

Self-limited inflammation

RBILD

Page 97: Case Presentations 2

Stable/indolent fibrotic disease

Fibrotic NSIP

Page 98: Case Presentations 2

Major inflammation with

variable fibrosis

DIP COP

Page 99: Case Presentations 2

Inexorably progressive fibrosis

UIP

Page 100: Case Presentations 2

Explosive ILD

AIP, accelerated UIP

Page 101: Case Presentations 2

Conclusions: useful points for

clinicians (1)

• Biopsy is no longer the diagnostic gold standard

• Diagnosis of IIP is now multidisciplinary

• IPF can be diagnosed on HRCT in the majority of cases but a crucial sub-group have very atypical HRCT appearances

• RBILD can be diagnosed using a combination of clinical and HRCT data

• DIP and NSIP require a biopsy for diagnosis

Page 102: Case Presentations 2

Conclusions : useful points for

clinicians (2)

• NSIP should be classified according to the disease it most closely represents

• In a small OP subset, there is progression to inexorable fibrosis

• Prognosis is based upon the reconciliation of HRCT, biopsy and clinical data

• A simple pragmatic clinical classification underlies best management

• Biopsy when these key clinical distinctions are blurred

Page 103: Case Presentations 2

Case No. 6

Page 104: Case Presentations 2

• You are called to suggest additional therapeutic options after a patient just underwent a diagnostic and therapeutic thoracentesis.

• The patient is a 65-year-old man with a long-standing left pleural effusion.

• The patient has had thoracentesis for the effusion on several occasions over the last year.

Page 105: Case Presentations 2

• The most recent pleural fluid values from 6 weeks ago include:

A protein level of 2.9 g/dL (29.0 g/L),

Lactate dehydrogenase (LDH) level of 124 U/L (2.1 kat/L) (serum: 220 U/L, 3.7 kat/L), and

pH of 7.34.

All culture results and cytologic evaluations have been negative

Page 106: Case Presentations 2

• The patient notes that he is able to perform his daily activities without difficulty.

• He notes only a mild increase in dyspnea on exertion over the last year while climbing stairs; he notes no other respiratory symptoms.

• His past medical history includes hypertension and dyslipidemia, both well controlled with medications.

Page 107: Case Presentations 2

• He had three-vessel coronary artery bypass grafting 2½ years ago and currently has no anginal symptoms.

• His most recent echocardiogram 4 months ago shows good left ventricular function, with an ejection fraction of 50%.

• After today’s thoracentesis, he notes no new symptoms specifically, also noting that he has no shortness of breath or chest discomfort.

Page 108: Case Presentations 2

• The consulting physician has obtained a postthoracentesis chest radiograph

Page 109: Case Presentations 2

CT scan of the chest

Page 110: Case Presentations 2

• Upon review of prior chest radiographs postthoracentesis, findings are similar to the current radiograph; similarly, a prior CT scan postthoracentesis 4 months ago has findings similar to the current CT scan.

• Pleural fluid values now available include a WBC count of 986/mm3 (0.986 × 109/L), protein level of 2.8 g/dL (28.0 g/L), and LDH level of 80 U/L (1.3 kat/L) (serum: 140 U/L [2.3 kat/L]).

Page 111: Case Presentations 2

Which is the most appropriate therapeutic approach for this patient?

• Place two 32F chest tubes, apply 20 cm of water suction to each.

• B. Consult surgery to perform a decortication.

• C. Start indomethacin.

• D. No specific treatment, monitor.

Page 112: Case Presentations 2

• This patient has a chronic stable and nearly asymptomatic pleural effusion with a thickened visceral pleural surface seen both on the chest radiograph (best seen at the apex) and the CT scan, compatible with a diagnosis of a trapped lung.

• The space between the thickened visceral pleural surface and the parietal pleura (chest wall) could represent a pneumothorax ex vacuo, but does not reflect lung injury during thoracentesis with consequent air entry into the pleural space (iatrogenic pneumothorax).

Page 113: Case Presentations 2

• Given the patient’s nearly asymptomatic state, no specific treatment is warranted (choice D is correct). The incidence of trapped lung is unknown but likely higher than recognized.

• Events producing initial pleural inflammation such as pneumonia, including with empyema; hemothorax; or prior thoracic surgery, including coronary artery bypass grafting (CABG), as in this patient, precede the development of a trapped lung and usually have an accompanying exudative effusion.

Page 114: Case Presentations 2

• The lung may first become “entrapped,” demonstrating limited reexpansion and an active pleural inflammatory process.

• At this stage, therapy is directed at the active process. As the inflammatory process becomes temporally remote, if the visceral pleural fibrosis (fibrous pleural peel) does not resolve, the lung becomes trapped and will not fully re-expand.

Page 115: Case Presentations 2

• Pleural fluid fills the space between the lung and parietal pleura.

• In one series, the most common cause out of 11 cases of trapped lung was coronary artery bypass graft (CABG), with the other causes found to be uremia, thoracic radiation, pericardiectomy, and complicated parapneumonic effusion

Page 116: Case Presentations 2

• Pleural fluid analysis from patients with a trapped lung often reveals borderline exudative values, with one series noting a mean pleural fluid pH of 7.30, LDH level of 124 U/L (2.1 kat/L), and protein level of 2.9 g/dL (29 g/L).

• The fluid is paucicellular with a mononuclear cell predominance, including an elevated lymphocyte percentage ( 50%) in most patients.

• Pleural manometry usually shows an initial negative pleural pressure with a rapid and steep decline in pleural pressure as fluid is removed, reflecting the inability of the lung to re-expand.

Page 117: Case Presentations 2

• However, most clinicians do not perform manometry, and the diagnosis can be made by a chest radiograph or CT chest after thoracentesis, demonstrating a thickened pleural surface and an unexpanded lung, as in this patient.

• The time between the inciting pleural event (eg, CABG), chronic nature of the effusion, pleural fluid findings, and all the radiographic findings are compatible with a trapped lung, and not an entrapped lung, in this patient.

Page 118: Case Presentations 2

• Placement of chest tubes with application of negative pressure will not cause reexpansion of a trapped lung (choice A is incorrect).

• Indomethacin may be useful in the management of postcardiac injury syndrome (PCIS), but the clinical picture in this patient, which includes the chronic nature of this patient’s effusion and limited clinical symptoms, including no fever, make PCIS very unlikely (choice C is incorrect).

• The definitive therapy for a trapped lung is decortication to allow lung reexpansion. However, this is major surgery and should only be employed in patients with significant symptoms arising from the trapped lung (choice B is incorrect).

Page 119: Case Presentations 2

So the best management of this patient is

• Place two 32F chest tubes, apply 20 cm of water suction to each.

• B. Consult surgery to perform a decortication.

• C. Start indomethacin.

• D. No specific treatment, monitor.

Page 120: Case Presentations 2